This manual provides guidance on best practices to be followed in Ebola Care Units (ECUs)/Community Care Centres (CCCs). It is intended for health aid workers (including junior nurses and community health-care workers) and others providing care for patients in ECUs/CCCs. While the focus is on the ca...re and management of patients with Ebola Virus Disease (EVD), the care of patients with other causes of fever is also described.
more
Updated: 20 July 2019
Fact sheet also available in Arabic, French, Spanish, Portuguese, Chinese and Russian. For other language versions go to: http://www.who.int/mediacentre/factsheets/zika/en/
The key aim of this guideline is to present recommendations based on a critical evaluation of the evidence on emerging digital health interventions that are contributing to health system improvements, based on an assessment of the benefits, harms, acceptability, feasibility, resource use and equity... considerations.
This guideline urges readers to recognize that digital health interventions are not a substitute for functioning health systems, and that there are significant limitations to what digital health is able to address
more
In the mid-1980s, recognizing the limitations of traditional training and that the knowledge and skills acquired are not necessarily applied back in the workplace, MSH developed the Monitoring‐Training-Planning (MTP) approach to assist the Ecuadorian Ministry of Health to implement its Child Survi...val Program. Using the MTP approach, staff me
mbers learn to mobilize their own resources and to improve, incrementally, the management of medicines and other pharmaceuticals at their own facility.
more
The guide is presented in two parts:
Part 1. Principles of Operational Monitoring: Describes the key principles of operational monitoring, alongside the types of operational monitoring that may be performed and the information required within an OMP.
Part 2. Operational Monitorin...g Plan Development: Describes the stepwise development of an OMP for a water supply system, including the source, water treatment, intermediate storage, distribution and household. For illustration purposes, practical guidance is provided using a specimen water supply system considered to be representative of a conventional small- to medium-sized supply in a lower resource setting. This template may be used to develop system-specific OMPs for individual water supply systems.
more
This document offers guidance to Member States in the African region on the key steps used to conduct contact tracing related to the COVID-19 response. It is to be used by national and local health authorities in the implementation of tracing of contacts of probable and confirmed COVID-19 cases.
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...st issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022. Available in other languages https://apps.who.int/iris/handle/10665/361720
more
Advocacy report March 2011
303100 03/2011 E 1,000
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more